Prime Medicine (NASDAQ:PRME) Receives Buy Rating from Chardan Capital

Posted by Brenda Bartman on Sep 25th, 2026

Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a report issued on Friday, Benzinga reports. They presently have a $7.00 target price on the stock. Chardan Capital’s price objective would indicate a potential upside of 142.63% from the stock’s current price.

PRME has been the topic of a number of other reports. BMO Capital Markets assumed coverage on Prime Medicine in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 price objective on the stock. New Street Research set a $8.00 price target on shares of Prime Medicine in a research report on Monday, June 29th. Citigroup reissued a “market outperform” rating on shares of Prime Medicine in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Prime Medicine in a report on Monday, August 10th. Finally, TD Cowen restated a “buy” rating on shares of Prime Medicine in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Prime Medicine has a consensus rating of “Moderate Buy” and an average price target of $7.47.

Check Out Our Latest Stock Analysis on Prime Medicine

Prime Medicine Stock Performance

NASDAQ:PRME traded down $0.19 during mid-day trading on Friday, hitting $2.89. The stock had a trading volume of 6,015,218 shares, compared to its average volume of 2,932,288. Prime Medicine has a twelve month low of $2.67 and a twelve month high of $6.94. The stock has a market cap of $523.28 million, a price-to-earnings ratio of -2.72 and a beta of 2.34. The company’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $3.37.

Prime Medicine (NASDAQ:PRME – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). Prime Medicine had a negative net margin of 4,613.11% and a negative return on equity of 188.27%. The firm had revenue of $1.15 million for the quarter, compared to analyst estimates of $4.40 million. As a group, equities analysts forecast that Prime Medicine will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Prime Medicine

Hedge funds have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in shares of Prime Medicine by 15.5% in the second quarter. Arizona State Retirement System now owns 28,646 shares of the company’s stock worth $106,000 after purchasing an additional 3,855 shares during the period. Royal Bank of Canada raised its holdings in shares of Prime Medicine by 89.3% in the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock worth $32,000 after buying an additional 4,365 shares in the last quarter. ProShare Advisors LLC grew its stake in Prime Medicine by 37.0% during the fourth quarter. ProShare Advisors LLC now owns 26,158 shares of the company’s stock worth $91,000 after buying an additional 7,059 shares during the last quarter. Swiss National Bank increased its holdings in Prime Medicine by 5.0% during the 1st quarter. Swiss National Bank now owns 178,600 shares of the company’s stock valued at $622,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Glen Eagle Advisors LLC acquired a new stake in Prime Medicine during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine, Inc is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient.